Home > Gastroenterology > ECCO 2022 > Specific Therapeutic Strategies > Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy

Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy

Presented By
Dr Kristin Jørgensen, Akershus University Hospital, Norway
Conference
ECCO 2022
Trial
NOR-DRUM B
Proactive therapeutic drug monitoring (TDM) outperformed standard therapy in maintaining disease control in participants with immune-mediated inflammatory diseases (IMID) who were on infliximab maintenance therapy in the 52-week NOR-DRUM B trial. The results indicate that TDM should be used as a general strategy for patients on infliximab maintenance therapy. “It is not yet established whether proactive TDM improves clinical outcomes in patients who are on infliximab maintenance therapy,” said Dr Kristin Jørgensen (Akershus University Hospital, Norway) [1,2]. Therefore, the NOR-DRUM A and B randomised-controlled clinical trials (NCT03074656) assessed proactive TDM during the induction and maintenance phase of infliximab therapy in participants with IMID [2]. The NOR-DRUM A trial demonstrated a non significant difference between TDM and standard therapy d...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on